About
Mirror Biologics is an international biopharmaceutical company specialized in development and manufacturing of next generation immunotherapy products where the active ingredients are living immune cells. Its technology originally spun out from Hadassah-Hebrew University Medical Center in Jerusalem. The company operates a 21 CFR 1271-compliant blood donor and cell processing center and conduct research and development on the design and testing of novel bioreactors and commercial manufacturing systems.
Its next generation immunotherapy programs aim to harness the power of the human immune system to treat and prevent disease. The company has developed a patented immune cell, called AlloStim®, with powerful immunomodulatory properties that is used to educate and modify a patients’ own immune system to enable it to identify and destroy cancers and infectious organisms and to reprogram immune systems weakened by age or chronic infection.
Its immunomodulatory vaccine development programs are based upon its novel Mirror Effect® technology platform which is able to imprint a re-programmed immune response over an existing failed immune response of a diseased or elderly patient. This novel technology platform expands the indications and type of patients that might benefit from immunotherapy approaches beyond first generation CAR-T and checkpoint inhibitor approaches.
Mirror Biologics acquired all the assets of Immunovative Therapies.